mRNA 백신 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)

mRNA Vaccine Market (Application: Covid-19, and Others; and End-user: Government Entities, Private Hospitals & Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

US $ 5,795 ￦ 8,478,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795 ￦ 12,867,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795 ￦ 17,256,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

mRNA 백신 시장 - 조사 범위

TMR의 세계 mRNA 백신 시장에 대한 조사 보고서는 2024년부터 2034년까지 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 추세와 기회를 조사하여 2024년을 기준 연도로, 2034년을 예측 연도로 삼고 있습니다, 2018년부터 2034년까지 세계 mRNA 백신 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 mRNA 백신 시장의 연평균 복합 성장률(CAGR%)도 제공합니다.

이 보고서는 광범위한 조사를 통해 작성되었으며, 1차 조사에서는 KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체를 인터뷰하고, 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 문서 등을 참조하여 mRNA 백신 시장을 이해했습니다.

시장 현황
2023년 시장 규모	217억 달러
2034년 시장 가치	96억 달러
CAGR	-4.3%

이 보고서는 세계 mRNA 백신 시장 경쟁 구도를 심층적으로 분석합니다. 세계 mRNA 백신 시장에서 활동하는 주요 업체들이 확인되었으며, 각 업체는 다양한 속성으로 프로파일링되어 있습니다. 기업 개요, 재무 상태, 최근 동향, SWOT는 세계 mRNA 백신 시장의 기업들이 이 보고서에서 제공하는 속성입니다.

목차

제1장 서문

제2장 조사의 전제조건과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

• 서론
• 시장 개요
• 시장 역학
• 세계 시장 분석과 예측, 2020년-2034년
• Porter의 Five Forces 분석

제5장 주요 인사이트

• 기술 진보
• 파이프라인
• 지역/세계 별 규제 시나리오
• COVID-19 팬데믹의 산업에 대한 영향 분석

제6장 세계 시장 분석과 예측 : 용도별

• 서론과 정의
• 주요 조사 결과/발전
• 용도별 시장 매출 예측, 2020년-2034년
  • COVID-19
  • 기타
• 용도별 시장의 매력

제7장 세계 시장 분석과 예측 : 최종사용자별

• 서론과 정의
• 주요 조사 결과/발전
• 최종사용자별 시장 매출 예측, 2020년-2034년
  • 정부기관
  • 민간 병원 및 클리닉
  • 기타
• 최종사용자별 시장의 매력

제8장 세계 시장 분석과 예측 : 지역별

• 주요 조사 결과
• 지역별 시장 매출 예측
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• 국가/지역별 시장의 매력

제9장 북미 시장 분석과 예측

• 미국
• 캐나다

제10장 유럽 시장 분석과 예측

• 독일
• 영국
• 프랑스
• 스페인
• 이탈리아
• 기타 유럽

제11장 아시아태평양 시장 분석과 예측

• 중국
• 일본
• 인도
• 호주 및 뉴질랜드
• 기타 아시아태평양

제12장 라틴아메리카 시장 분석과 예측

• 브라질
• 멕시코
• 기타 라틴아메리카

제13장 중동 및 아프리카 시장 분석과 예측

• GCC 국가
• 남아프리카공화국
• 기타 중동 및 아프리카

제14장 경쟁 구도

• 시장 경쟁 매트릭스(Tier별, 기업 규모별)
• 기업 점유율 분석(2022년)
• 기업 개요
  • Pfizer, Inc.
  • Moderna Inc.
  • Novartis AG
  • Sanofi
  • Arcturus Therapeutics
  • Gennova Biopharmaceuticals Ltd
  • Aimei Vaccine Co., Ltd

LSH

영문 목차

영문목차

mRNA Vaccine Market - Scope of Report

TMR's report on the global mRNA vaccine market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global mRNA vaccine market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global mRNA vaccine market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the mRNA vaccine market.

Market Snapshot
Market Value in 2023	US$ 21.7 Bn
Market Value in 2034	US$ 9.6 Bn
CAGR	-4.3%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global mRNA vaccine market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global mRNA vaccine market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global mRNA vaccine market.

The report delves into the competitive landscape of the global mRNA vaccine market. Key players operating in the global mRNA vaccine market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global mRNA vaccine market profiled in this report.

Key Questions Answered in Global mRNA vaccine Market Report:

• What is the sales/revenue generated by mRNA vaccine across all regions during the forecast period?
• What are the opportunities in the global mRNA vaccine market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

mRNA Vaccine Market - Research Objectives and Research Approach

The comprehensive report on the global mRNA vaccine market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global mRNA vaccine market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global mRNA vaccine market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global mRNA Vaccine Market

4. Market Overview

• 4.1. Introduction
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global mRNA Vaccine Market Analysis and Forecasts, 2020-2034
• 4.5. Porter's Five Force Analysis

5. Key Insights

• 5.1. Technological Advancements
• 5.2. mRNA Vaccines Pipeline
• 5.3. Regulatory Scenario by Region/Globally
• 5.4. COVID-19 Pandemic Impact Analysis on Industry

6. Global mRNA Vaccine Market Analysis and Forecasts, By Application

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Application, 2020-2034
  • 6.3.1. COVID-19
  • 6.3.2. Others
• 6.4. Market Attractiveness By Application

7. Global mRNA Vaccine Market Analysis and Forecasts, By End-user

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By End-user, 2020-2034
  • 7.3.1. Government Entities
  • 7.3.2. Private Hospitals & Clinics
  • 7.3.3. Others
• 7.4. Market Attractiveness By End-user

8. Global mRNA Vaccine Market Analysis and Forecasts, By Region

• 8.1. Key Findings
• 8.2. Market Value Forecast By Region
  • 8.2.1. North America
  • 8.2.2. Europe
  • 8.2.3. Asia Pacific
  • 8.2.4. Latin America
  • 8.2.5. Middle East & Africa
• 8.3. Market Attractiveness By Country/Region

9. North America mRNA Vaccine Market Analysis and Forecast

• 9.1. Introduction
  • 9.1.1. Key Findings
• 9.2. Market Value Forecast By Application, 2020-2034
  • 9.2.1. COVID-19
  • 9.2.2. Others
• 9.3. Market Value Forecast By End-user, 2020-2034
  • 9.3.1. Government Entities
  • 9.3.2. Private Hospitals & Clinics
  • 9.3.3. Others
• 9.4. Market Value Forecast By Country, 2020-2034
  • 9.4.1. U.S.
  • 9.4.2. Canada
• 9.5. Market Attractiveness Analysis
  • 9.5.1. By Application
  • 9.5.2. By End-user
  • 9.5.3. By Country

10. Europe mRNA Vaccine Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast By Application, 2020-2034
  • 10.2.1. COVID-19
  • 10.2.2. Others
• 10.3. Market Value Forecast By End-user, 2020-2034
  • 10.3.1. Government Entities
  • 10.3.2. Private Hospitals & Clinics
  • 10.3.3. Others
• 10.4. Market Value Forecast By Country, 2020-2034
  • 10.4.1. Germany
  • 10.4.2. U.K.
  • 10.4.3. France
  • 10.4.4. Spain
  • 10.4.5. Italy
  • 10.4.6. Rest of Europe
• 10.5. Market Attractiveness Analysis
  • 10.5.1. By Application
  • 10.5.2. By End-user
  • 10.5.3. By Country

11. Asia Pacific mRNA Vaccine Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast By Application, 2020-2034
  • 11.2.1. COVID-19
  • 11.2.2. Others
• 11.3. Market Value Forecast By End-user, 2020-2034
  • 11.3.1. Government Entities
  • 11.3.2. Private Hospitals & Clinics
  • 11.3.3. Others
• 11.4. Market Value Forecast By Country, 2020-2034
  • 11.4.1. China
  • 11.4.2. Japan
  • 11.4.3. India
  • 11.4.4. Australia & New Zealand
  • 11.4.5. Rest of Asia Pacific
• 11.5. Market Attractiveness Analysis
  • 11.5.1. By Application
  • 11.5.2. By End-user
  • 11.5.3. By Country

12. Latin America mRNA Vaccine Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Application, 2020-2034
  • 12.2.1. COVID-19
  • 12.2.2. Others
• 12.3. Market Value Forecast By End-user, 2020-2034
  • 12.3.1. Government Entities
  • 12.3.2. Private Hospitals & Clinics
  • 12.3.3. Others
• 12.4. Market Value Forecast By Country, 2020-2034
  • 12.4.1. Brazil
  • 12.4.2. Mexico
  • 12.4.3. Rest of Latin America
• 12.5. Market Attractiveness Analysis
  • 12.5.1. By Application
  • 12.5.2. By End-user
  • 12.5.3. By Country

13. Middle East & Africa mRNA Vaccine Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Application, 2020-2034
  • 13.2.1. COVID-19
  • 13.2.2. Others
• 13.3. Market Value Forecast By End-user, 2020-2034
  • 13.3.1. Government Entities
  • 13.3.2. Private Hospitals & Clinics
  • 13.3.3. Others
• 13.4. Market Value Forecast By Country, 2020-2034
  • 13.4.1. GCC Countries
  • 13.4.2. South Africa
  • 13.4.3. Rest of Middle East & Africa
• 13.5. Market Attractiveness Analysis
  • 13.5.1. By Application
  • 13.5.2. By End-user
  • 13.5.3. By Country

14. Competition Landscape

• 14.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 14.2. Market Share Analysis By Company (2022)
• 14.3. Company Profiles
  • 14.3.1. Pfizer, Inc.
    • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.1.2. Product Portfolio
    • 14.3.1.3. Financial Overview
    • 14.3.1.4. SWOT Analysis
    • 14.3.1.5. Strategic Overview
  • 14.3.2. Moderna Inc.
    • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.2.2. Product Portfolio
    • 14.3.2.3. Financial Overview
    • 14.3.2.4. SWOT Analysis
    • 14.3.2.5. Strategic Overview
  • 14.3.3. Novartis AG
    • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.3.2. Product Portfolio
    • 14.3.3.3. Financial Overview
    • 14.3.3.4. SWOT Analysis
    • 14.3.3.5. Strategic Overview
  • 14.3.4. Sanofi
    • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.4.2. Product Portfolio
    • 14.3.4.3. Financial Overview
    • 14.3.4.4. SWOT Analysis
    • 14.3.4.5. Strategic Overview
  • 14.3.5. Arcturus Therapeutics
    • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.5.2. Product Portfolio
    • 14.3.5.3. Financial Overview
    • 14.3.5.4. SWOT Analysis
    • 14.3.5.5. Strategic Overview
  • 14.3.6. Gennova Biopharmaceuticals Ltd
    • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.6.2. Product Portfolio
    • 14.3.6.3. Financial Overview
    • 14.3.6.4. SWOT Analysis
    • 14.3.6.5. Strategic Overview
  • 14.3.7. Aimei Vaccine Co., Ltd
    • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.7.2. Product Portfolio
    • 14.3.7.3. Financial Overview
    • 14.3.7.4. SWOT Analysis
    • 14.3.7.5. Strategic Overview

관련자료